Boom baby!

SmallCapFirm

Could These 4 Potential Catalysts Spark Low Float Nasdaq Idea (INM) To A Near Term Vertical Surge?

Edison Group INM Price Target - $20.53

April 21st

SCF Readers,

Boom baby!

Were you ready to roll Tuesday morning at the opening bell? If you were, you had a front row seat to an explosive intraday profile in QIPT.

Opening at $4.29, it ran all the way to a high of $5.00 on the day for an approximate surge of 16% intraday.

While that was going on, I was hot on the tracks of another Nasdaq profile and potential breakout candidate.

And guess what... I'm thinking I've come across something special.

With a low float, key chart position, a major analyst price target, an important acquisition and more, you will not want to wait to pull up this profile.

Plus, with the global cann-a-binoid synthesis market estimated to grow from $10Bn in 2025 to $115Bn by 2040 (1), this company could be in the right place at the right time.

For Thursday, April 21st, there is only one profile to have at the top of your watch-list:

*InMed Pharmaceuticals Inc. (INM)*

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cann-a-binoids.

Together with its subsidiary BayMedica LLC, the Company has unparalleled cann-a-binoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness.

InMed is also a clinical-stage company developing a pipeline of rare cann-a-binoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cann-a-binoid-based pharmaceutical dr-ugs.

And right now it has several key potential catalyst that could fuel a vertical move in the near term. Check them out:

No. 1 - Research Firm Edison Group Provides Huge $20+ Price Target

No. 2 - Another Low Float Profile

No. 3 - Important Shareholder Update Highlighting Key Accomplishments

No. 4 - Company Launches B2B Sales Of CBT

But more on those in a second...

InMed Pharmaceuticals (INM): Unparalleled Cann-a-binoid Manufacturing Expertise

To put it simply, no one manufacturing approach fits all.

Multiple avenues are needed to select the most effective manufacturing method based on target cann-a-binoids and the appropriate quality specifications for the desired market segment.

And THIS is where InMed has a leg up on the competition. By acquiring BayMedica, the company has 3 different types of manufacturing avenues:

image

Now, the company has already launched rare cann-a-binoids in CBC and CBT to multiple business customers in the consumer health and wellness space, but InMed’s pipeline could be really big news moving forward.

But more important is the scale and purity of the CB-DV and TH-CV. CB-DV is structurally similar to CB-D (cann-a-bidiol). Like CB-D, CB-DV is not intoxicating when isolated, so it won’t cause the euphoric high associated with high-TH-C cann-a-bis.

That means there is ZERO RISK of having or being associated with a controlled substance. Just take a look and see what the future may hold:

image

Just know, there are over 100 rare cann-a-binoids out there. This could be only the start of something even bigger.

Read The Full Company Presentation Here.

-----

Right now, INM has several potential catalysts to be aware of. Here they are:

No. 1 INM Potential Catalyst - Research Firm Edison Group Provides Huge $20+ Price Target

"Huge" might be an understatement here.

Edison group slapped a $20.53 price target on INM towards the end of last year which provides this profile with a stunning 1900+% potential upside from Wednesday's closing valuation.

Here's some highlights from the report:

  • Following InMed’s acquisition of BayMedica, the combined company has multiple manufacturing approaches to produce rare cann-a-binoids at meaningful yields and at attractive costs and has a growing commercial product pipeline. It is currently the global leader in large batch (currently 200kg but with the ability to scale up to metric tonnes) supply of CBC, a rare non-intoxicating cann-a-binoid. It is currently being marketed to consumer health and wellness companies for the nutraceuticals, cosmetics, functional food/beverages and animal health markets.
  • The company announced in late September it has initiated the 755-201-EB trial, which will test INM-755 in up to 20 EB patients with an anticipated treatment duration of 28 days. The study is currently expected to take place across 11 sites in seven countries, with patient screening underway at the first site.
  • With regards to INM-088 for glaucoma, the company has continued to set up a larger-scale dr-ug manufacturing process, and has completed dose-ranging studies and conducted topline clinical study design work. Regulatory applications to initiate human clinical testing are expected to be filed in the second half of CY22.
  • We have adjusted our valuation to US$290m or US$20.53 per basic share, from US$293m or US$24.24 per basic share. This is mainly due to a higher number of shares outstanding following the share issuance as a result of the closure of the BayMedica acquisition. In addition, there was a decline in net cash. InMed had US$15.4m in cash and marketable securities at 30 September 2021. We currently model an additional US$11m being raised in FY23, though the exact funding requirement will depend on the expense level for the combined companies. We will update our fin-an-cial model once BayMedica fin-an-cials are included in regulatory filings, which is likely to occur with the next quarterly report.

-----

No. 2 INM Potential Catalyst - Another Low Float Profile

According to the Yahoo Finance website, INM has a low float.

The website reports this profile to have approximately 13.74Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.

-----

No. 3 INM Potential Catalyst - Important Shareholder Update Highlighting Key Accomplishments

InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook

VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cann-a-binoids, today issued the following letter from President and CEO Eric A. Adams.

Dear Shareholders, Colleagues, and Business Partners,

I’d like to start off by sending you warm wishes for a healthy and prosperous 2022. While another wave of the CV-19 pandemic continues to bring global uncertainty and an ever-evolving business environment, we remain true to our fundamental principles of bringing short- and long-term value to our shareholders.

[...]

I’m very excited to provide updates on our progress as we begin to commercialize new products and explore an array of rare cann-a-binoids for their potential therapeutic applications.

Acquisition of BayMedica, Creating a Leader in Rare Cann-a-binoid Manufacturing

The acquisition of BayMedica in October 2021 brings InMed tremendous commercial opportunities and we believe has positioned the Company as a clear leader in rare cann-a-binoid manufacturing. This combination of companies is an excellent match – bringing together synergistic programs and expertise that will accelerate and strengthen the combined cann-a-binoid programs. The acquisition of BayMedica sets the stage for a number of key business initiatives:

  • Positions the company as a global leader in the research, development and commercialization of rare cann-a-binoids;
  • Provides an immediate revenue stream through the B2B sale of rare cann-a-binoids in the health and wellness sector;
  • Strengthens and diversifies our rare cann-a-binoid manufacturing capabilities and expertise with the addition of yeast biosynthesis and chemical synthesis;
  • Provides access to proprietary, patent-pending novel cann-a-binoid analogs for pharmaceutical drug development; and
  • Adds significant, multifaceted expertise to our team across a variety of research and business functions.

This acquisition was a natural fit. The combination of our pharma-grade manufacturing process, IntegraSyn™, and BayMedica’s revenue-generating, consumer-focused processes that may also be suitable as a basis for pharmaceutical applications, create a strong platform for significant growth in the cann-a-binoid manufacturing space.

BayMedica’s team brings extensive expertise that strengthens both our pharmaceutical drug development efforts and our continued exploration of rare cann-a-binoids. In addition to growing BayMedica’s commercial activities, we continue to focus on the research and development of cann-a-binoid analogs and new chemical entities for pharmaceutical purposes.

IntegraSyn™: Maximizing Production Yield

We continue to make significant strides with our IntegraSyn™ program and hit several milestones throughout 2021. In June, we announced that IntegraSyn™ was capable of producing an industry-leading yield of 5 g/L. This significantly reduces the cost of the manufacturing process, which will enable more efficient large-scale production.

Our goal is to optimize this platform for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP”) production of rare cann-a-binoids, with the potential to integrate with BayMedica’s biosynthesis or chemical synthesis manufacturing approaches. With these diverse technologies, we have a breadth of synthetic cann-a-binoid manufacturing capabilities to deliver high-quality, cost-effective rare cann-a-binoids for any segment of the market from consumer packaged goods to prescription pharmaceuticals.

Advancing Our Pharmaceutical Programs

Our pharmaceutical drug development programs are integral to our business. The FDA approval pathway takes significant time and investment but, if successful, the outcome can be very rewarding - not only for the lives of those whom we may impact, but also for the potential value creation for our shareholders.

The library of novel cann-a-binoid analogs developed by BayMedica gives our pharmaceutical program added strength. We are one of only a few companies to advance a rare cann-a-binoid into clinical trials. Access to BayMedica’s library of proprietary rare cann-a-binoids, coupled with our cann-a-binoid clinical experience, positions us to lead the industry in the clinical development of rare cann-a-binoids.

INM-755 Program for the Treatment of Epidermolysis Bullosa (“EB”): Phase 2 Trial Initiated

We’ve made great strides with our INM-755 program over the past year. Our top-line results from our second Phase 1 clinical study, indicating that INM-755 was safe and well-tolerated on induced open epidermal wounds, causing no serious adverse effects, set the groundwork to move forward to a Phase 2 efficacy trial, which we initiated in September of 2021. This marks the first time cann-a-binol (CBN) has advanced into a Phase 2 clinical trial to be studied as a therapeutic option to treat a disease, a key milestone as we continued to explore the therapeutic benefits of this class of compounds. The Phase 2 study will be enrolling and treating EB patients at thirteen targeted sites across multiple countries throughout 2022.

INM-088 Program for the Treatment of Glaucoma: Potential Blockbuster

Throughout 2021, we continued to advance INM-088 towards human clinical trials for glaucoma. Our team conducted important preclinical studies that validated the use of cann-a-binol (CBN) for glaucoma. Our studies show that CBN has the potential to be an effective neuroprotective agent for the retina ganglion cells and to reduce intraocular pressure in preclinical glaucoma models. InMed’s preclinical studies were recently published in a leading international journal. In this peer-reviewed scientific article, entitled “Cann-a-binol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma”, the study results demonstrated that CBN has strong potential as a glaucoma treatment and was more effective than CB-D and TH-C in these studies. This peer-reviewed research is a significant milestone for our glaucoma program, providing important external validation and highlighting the importance of finding a new treatment for this damaging eye disease that affects approximately 80 million people worldwide.

In addition, we have completed several dose-ranging studies and conducted topline clinical study design work with a leading clinical research organization. Key next steps for this program include seeking regulatory authority input into our proposed preclinical data package and preliminary clinical trial designs.

[...]

Read the full shareholder update here.

-----

No. 4 INM Potential Catalyst - Company Launches B2B Sales Of CBT

InMed Launches Canna-b-icitran (CBT), Expanding its Rare Cann-a-binoid Portfolio for the Health and Wellness Sector

  • CBT is the first of several rare cann-a-binoid launches planned for the first half of 2022; includes CB=DV and TH=CV
  • Expands the Company’s rare cann-a-binoid product portfolio, which also includes cann-a-bichromene (CBC)
  • Strengthens leadership position in commercial scale production of high demand rare cann-a-binoids

VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cann-a-binoids, is pleased to announce it has launched B2B sales of the rare cann-a-binoid cann-a-bicitran (CBT) into the health and wellness sector. CBT is the first of several new product launches planned for the first half of 2022.

InMed’s subsidiary, BayMedica, has received initial purchase orders and has commenced commercial sales of the ultra-rare cann-a-binoid CBT. CBT is the second rare cann-a-binoid to be launched by BayMedica, which also sells CBC wholesale as a raw ingredient to the health and wellness sector. Additionally, commercial scale production of cann-a-bidivarin (CB-DV) is underway, with tetra-hydrocanna-bivarin (TH-CV) production scheduled to follow shortly thereafter. The Company expects to produce over 100kg of CB-DV and TH-CV in the coming months to meet anticipated initial demand.

We are delivering on our objective to launch additional rare cann-a-binoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cann-a-binoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cann-a-binoids in these sectors,” stated Shane Johnson, SVP and General Manager of BayMedica. “The launch of CBT further demonstrates our ability to produce rare cann-a-binoids at commercial scale, an achievement that very few companies have been able to accomplish. We are pleased with initial demand and we expect to grow sales over the coming quarters as we continue to expand our product portfolio of rare cann-a-binoids.

[...]

Read the full article here.

-----

Nasdaq Profile Recap - Top 4 INM Potential Catalysts

No. 1 - Research Firm Edison Group Provides Huge $20+ Price Target

No. 2 - Another Low Float Profile

No. 3 - Important Shareholder Update Highlighting Key Accomplishments

No. 4 - Company Launches B2B Sales Of CBT

-----

Coverage is officially initiated on INM. When you have time later, do this:

image

Get INM on your radar now.

Sincerely,

Axel Adams

Editor, SCF


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 4/21/22 and ending on 4/22/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid thirty thousand USD via bank wire transfer. We own zero shares of (INM). Pursuant to an agreement between StockNewsWire, LLC and Awareness Consulting Network, LLC., StockWireNews was hired for a period beginning on 11/8/21 and ending on 11/9/21 to publicly disseminate information about (QIPT) via Website, Email and SMS. We were paid ten thousand USD via bank wire transfer. We own zero shares of (QIPT). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 4/19/22 and ending on 4/20/22 to publicly disseminate information about (QIPT) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (QIPT). To date we have now been compensated a total of thirty-seven thousand five hundred USD via bank wire transfer to disseminate information about (QIPT).